BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors

Heterozygous germline mutations in BRCA2 predispose to breast and ovarian cancer. Contrary to non-cancerous cells, where BRCA2 deletion causes cell cycle arrest or cell death, tumors carrying BRCA2 inactivation continue to proliferate. Here we set out to investigate adaptation to loss of BRCA2 focus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Reisländer, Timo, Lombardi, Emilia Puig, Groelly, Florian J., Miar, Ana, Porru, Manuela, Di Vito, Serena, Wright, Benjamin, Lockstone, Helen, Biroccio, Annamaria, Harris, Adrian, Londoño-Vallejo, Arturo, Tarsounas, Madalena
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6637138/
https://ncbi.nlm.nih.gov/pubmed/31316060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-11048-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados